571168-92-8Relevant articles and documents
Practical Pd/C-catalysed suzuki-miyaura reactions for the preparation of 3-aryl-4-oxypyridin-2(1H)-ones, 3-aryl-2,4-oxypyridines and 3-aryl-2,4- oxyquinolines as useful intermediates for the synthesis of biologically active compounds
Lamblin, Marc,Bares, Hugo,Dessolin, Jean,Marty, Christel,Bourgougnon, Nathalie,Felpin, Francois-Xavier
, p. 5525 - 5533 (2012/10/29)
Practical heterogeneous Pd/C-catalysed Suzuki-Miyaura cross-coupling reactions of 3-iodo-4-oxypyridin-2(1H)-ones, 3-iodo-2,4-oxypyridines, and 3-iodo-2,4-oxyquinolines with arylboronic acids are described as a useful and efficient alternative to homogeneous conditions. The methodology features ligand-free and environmentally friendly conditions, and tolerates a wide range of boronic acids. The cross-coupled products can be viewed as useful intermediates for the preparation of 3-aryl-4-hydroxypyridin-2(1H)-ones, which can be used as new nucleobases for antiherpetic agents.
Discovery of N-substituted pyridinones as potent and selective inhibitors of p38 kinase
Selness, Shaun R.,Devraj, Rajesh V.,Monahan, Joseph B.,Boehm, Terri L.,Walker, John K.,Devadas, Balekudru,Durley, Richard C.,Kurumbail, Ravi,Shieh, Huey,Xing, Li,Hepperle, Michael,Rucker, Paul V.,Jerome, Kevin D.,Benson, Alan G.,Marrufo, Laura D.,Madsen, Heather M.,Hitchcock, Jeff,Owen, Tom J.,Christie, Lance,Promo, Michele A.,Hickory, Brian S.,Alvira, Edgardo,Naing, Win,Blevis-Bal, Radhika
scheme or table, p. 5851 - 5856 (2010/07/05)
The identification and evolution of a series of potent and selective p38 inhibitors is described. p38 inhibitors based on a N-benzyl pyridinone high-throughput screening hit were prepared and their SAR explored. Their design was guided by ligand bound co-
SUBSTITUTED PYRIDINONES
-
Page/Page column 265, (2008/06/13)
Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and R5 are defined herein. These compounds are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical compositions containing the compounds, methods of preparing the compounds and methods of treatment using the compounds are also disclosed.